67 related articles for article (PubMed ID: 2227622)
21. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
[TBL] [Abstract][Full Text] [Related]
22. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
[TBL] [Abstract][Full Text] [Related]
23. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
de la Rubia J; Sanz GF; Martín G; Sempere A; Picón I; Carral A; Larrea L; Martínez J; Soler MA; Bonanad S; López F; Jarque I; Sanz MA
Bone Marrow Transplant; 1996 Dec; 18(6):1167-73. PubMed ID: 8971390
[TBL] [Abstract][Full Text] [Related]
24. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
25. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
[TBL] [Abstract][Full Text] [Related]
26. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
[TBL] [Abstract][Full Text] [Related]
28. Management of acute promyelocytic leukemia relapse in the ATRA era.
Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
[TBL] [Abstract][Full Text] [Related]
29. Acute nonlymphocytic leukemia in the elderly: results of a retrospective study.
Latagliata R; Sgadari C; Pisani F; Falconi M; Spadea A; Vegna ML; Petti MC
Haematologica; 1989; 74(2):167-71. PubMed ID: 2501170
[TBL] [Abstract][Full Text] [Related]
30. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Feldman EJ; Brandwein J; Stone R; Kalaycio M; Moore J; O'Connor J; Wedel N; Roboz GJ; Miller C; Chopra R; Jurcic JC; Brown R; Ehmann WC; Schulman P; Frankel SR; De Angelo D; Scheinberg D
J Clin Oncol; 2005 Jun; 23(18):4110-6. PubMed ID: 15961759
[TBL] [Abstract][Full Text] [Related]
31. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
32. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
34. Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
Jehn U; Heinemann V
Ann Hematol; 1993 Mar; 66(3):131-4. PubMed ID: 8471658
[TBL] [Abstract][Full Text] [Related]
35. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
Capizzi RL; Davis R; Powell B; Cuttner J; Ellison RR; Cooper MR; Dillman R; Major WB; Dupre E; McIntyre OR
J Clin Oncol; 1988 Mar; 6(3):499-508. PubMed ID: 3162515
[TBL] [Abstract][Full Text] [Related]
36. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
Martiat P; Ghilain JM; Ferrant A; Doyen C; Delannoy A; Chatelain C; Bosly A; Michaux JL; Sokal G
Eur J Haematol; 1990 Sep; 45(3):164-7. PubMed ID: 2226729
[TBL] [Abstract][Full Text] [Related]
37. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
Mirro J; Kalwinsky DK; Grier HE; Santana VM; Mason C; Murphy SB; Dahl GV
Cancer Chemother Pharmacol; 1989; 24(2):123-7. PubMed ID: 2731312
[TBL] [Abstract][Full Text] [Related]
38. [Phase II clinical trial of domestic amsacrine in patients with acute leukemias. Cooperative Group for Treating Acute Leukemias with Domestic m-AMSA].
Zhonghua Nei Ke Za Zhi; 1993 Feb; 32(2):80-4. PubMed ID: 8404329
[TBL] [Abstract][Full Text] [Related]
39. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Liang R; Chan TK; Todd D
Cancer Chemother Pharmacol; 1988; 21(1):68-70. PubMed ID: 3342467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
